Mrs Sarah E Morrison, OTR/L in Waitsfield, VT - Occupational Therapist

Mrs Sarah E Morrison, OTR/L is a Occupational Therapist - Pediatrics based in Waitsfield, Vermont. Mrs Sarah E Morrison is licensed to practice in Vermont (license number 072.0101876) and her current practice location is 242 Pinebrook Rd, Waitsfield, Vermont. She can be reached at her office (for appointments etc.) via phone at (970) 509-0485.

NPI number for Mrs Sarah E Morrison is 1346587748 and her current mailing address is 242 Pinebrook Rd, Waitsfield, Vermont. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1346587748.

Contact Information

	Mrs Sarah E Morrison, OTR/L
	242 Pinebrook Rd, Waitsfield, VT 05673-6052
	(970) 509-0485
	Not Available

Healthcare Provider's Profile

Full Name	Mrs Sarah E Morrison
Gender	Female
Speciality	Occupational Therapist - Pediatrics
Location	242 Pinebrook Rd, Waitsfield, Vermont
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1346587748
Provider Enumeration Date: 01/07/2013
Last Update Date: 05/23/2016

Medical Identifiers

Medical identifiers for Mrs Sarah E Morrison such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1346587748	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225XP0200X	Occupational Therapist - Pediatrics	072.0101876 (Vermont)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Sarah E Morrison is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Sarah E Morrison, OTR/L 242 Pinebrook Rd, Waitsfield, VT 05673-6052 Ph: () -	Mrs Sarah E Morrison, OTR/L 242 Pinebrook Rd, Waitsfield, VT 05673-6052 Ph: (970) 509-0485

News Archive

Pawlenty makes 'Obamneycare' a buzz word in contest for GOP presidential nomination

The Los Angeles Times predicts that the GOP candidates will be making "bold right turns" during Monday night's New Hampshire debate, which is considered the first major debate of the 2012 campaign. In advance of this contest, former Minnesota Gov. Tim Pawlenty took swipes at former Mass. Gov. Mitt Romney — connecting his state health overhaul to that of the federal health law.

Study on leisure experiences of women with intellectual disabilities in group homes

Brenda Rossow-Kimball, who did post-graduate research with Donna Goodwin, in the Faculty of Physical Education and Recreation, investigated the leisure experiences of five women with intellectual disabilities in two group homes. They found major differences in how leisure was experienced in each group home. In one, the women were provided with support and encouraged to make their own decisions about how they used their leisure time; there was a genuine interest in the women engaging in independent spontaneous leisure, according to Rossow-Kimball. In the other home leisure was supervised by the staff, scheduled into the activities of the home, and managed by the staff, which, the researchers say, doesn't teach the women how to discover what they like to do for leisure.

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Cyclin D1, a protein that helps push a replicating cell through the cell cycle also mediates the processing and generation of mature microRNA, according to new research publishing November 29 in Nature Communications. The research suggests that a protein strongly implicated in human cancer also governs the non-protein-coding genome. The non-coding genome, previously referred to as junk DNA, makes up most of the human genome, and unlike the coding genome, varies greatly between species.

Abbott and AstraZeneca to co-promote Trilipix (fenofibric acid)

Abbot and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott's Trilipix (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote Trilipix alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

TLR7, TLR9 proteins could be culprit behind lupus patients' resistance to steroid treatments: Scientists

Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide.

Mrs Sarah E Morrison, OTR/L - Occupational Therapist in Waitsfield, VT